This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Leland Stanford Junior University. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Rebecca Richards
Introduction
Rebecca Richards is a prominent inventor based in Portola Valley, California. She has made significant strides in the field of therapeutic proteins, particularly in the development of antigen binding proteins specific for CD93. Her work has the potential to impact cancer treatment, especially for hematologic malignancies.
Latest Patents
Rebecca Richards holds a patent for "Therapeutic antigen binding proteins specific for CD93 and methods of use thereof." This patent includes antigen binding domain polypeptides (ABD) that are specific for human CD93. These ABDs can be formatted as antibodies or chimeric antigen receptors, which are crucial for the advancement of T cell therapies in cancer treatment.
Career Highlights
Richards is affiliated with Leland Stanford Junior University, where she continues her research and development in the field of immunotherapy. Her innovative approach to targeting CD93 has garnered attention in the scientific community and has opened new avenues for cancer treatment.
Collaborations
Rebecca has collaborated with notable colleagues such as Ravindra Majeti and Crystal L Mackall. Their combined expertise enhances the research efforts in developing effective cancer therapies.
Conclusion
Rebecca Richards is a trailblazer in the field of therapeutic proteins, with her patent and research contributing significantly to cancer treatment advancements. Her work exemplifies the impact of innovation in medicine and the importance of collaboration in scientific research.